Please login to the form below

Not currently logged in
Email:
Password:

CMPT announces CEO and loan investment

CMP Therapeutics has announced that Dr Neill Moray Mackenzie will become CEO and that the company will receive a €1.5m convertible loan investment

CMP Therapeutics (CMPT) has appointed Dr Neill Moray Mackenzie to the role of CEO, replacing Dr Bruce Savage, who leaves CMPT to concentrate on his other portfolio companies.

Dr Mackenzie brings to CMPT experience at executive board level in both the biotechnology and pharmaceutical industries. He has held roles at Cambridge Genetics, Oxford Biomedica, Avidex (now Immunocore) and, most recently, was senior vice president for business development and corporate strategy at Medigene and CEO of Roji (London).

Dr MacKenzie was also a departmental head in vaccine R&D at Wellcome and a Wellcome Lecturer in immunology at the University of London.

In addition, CMPT has announced that the company will receive an injection of €1.5m in the form of a convertible loan from Inventages Venture Capital, which will be used to support continuing operations and the upcoming clinical trial of its lead product for the common cold.

Since 2005 CMPT has been supported solely by investments from London-based Inventages Venture Capital and New Zealand-based BioPacificVentures.

2nd August 2010

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Just::Health Communications

Just:: is a different kind of healthcare communications agency. Since 2006, we’ve been collaborating with clients around the world to...

Latest intelligence

International Childhood Cancer Day 2019
The number of new cases per year is shocking but the journey and the outlooks have vastly improved. We've pulled together an infographic to show just what we mean with...
Immuno-oncology in 2019: the rapid evolution continues
Immunotherapy is pharma’s biggest growth driver – how will it develop in 2019?...
Mixing up Focus Groups
A nice spread of homogeneous participants in a focus groups are often a go to for reliable research outcomes but there's much to be said for mixing it up and...

Infographics